Lurasidone for the treatment of bipolar depression: an evidence-based review

References

• MerikangasKRAkiskalHSAngstJLifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replicationArch Gen Psychiatry200764554355217485606
   PubMed Web of Science ®Google Scholar
• 2007 World Population Data Sheet Available from: http://www.prb.org/Publications/Datasheets/2007/2007WorldPopulationDataSheet.aspxAccessed March 23, 2015
   Google Scholar
• VosTFlaxmanADNaghaviMYears lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010Lancet201338098592163219623245607
   PubMed Web of Science ®Google Scholar
• AltamuraACSeratiMAlbanoAPaoliRAGlickIDDell’OssoBAn epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychosesEur Arch Psychiatry Clin Neurosci2011261748950821331479
   PubMed Web of Science ®Google Scholar
• KleinmanLSLowinAFloodEGandhiGEdgellERevickiDACosts of bipolar disorderPharmacoeconomics200321960162212807364
   PubMed Web of Science ®Google Scholar
• Inflation Calculator: Bureau of Labor Statistics Available from: http://www.bls.gov/data/inflation_calculator.htmAccessed March 26, 2015
   Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders (DSM)5th edArlington, VAAmerican Psychiatric Publishing2013
   Google Scholar
• JuddLLAkiskalHSSchettlerPJThe long-term natural history of the weekly symptomatic status of bipolar I disorderArch Gen Psychiatry200259653053712044195
   PubMed Web of Science ®Google Scholar
• CalabreseJRHirschfeldRFryeMAReedMLImpact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a US community-based sampleJ Clin Psychiatry200465111499150415554762
   PubMed Web of Science ®Google Scholar
• El-MallakhRSGhaemiSNBipolar Depression: A Comprehensive GuideAmerican Psychiatric Publishing2007 Available from: http://books.google.com/books?id=fFKgiZU2KscC
   Google Scholar
• TondoLIsacssonGBaldessariniRJSuicidal behaviour in bipolar disorderCNS Drugs200317749151112751919
   PubMed Web of Science ®Google Scholar
• MalhiGSAdamsDBerkMMedicating mood with maintenance in mind: bipolar depression pharmacotherapyBipolar Disord200911s2557619538686
   PubMed Web of Science ®Google Scholar
• BeyerJLAn evidence-based medicine strategy for achieving remission in bipolar disorderJ Clin Psychiatry200769313718533760
   PubMed Web of Science ®Google Scholar
• WooYSWangHRBahkW-MLurasidone as a potential therapy for bipolar disorderNeuropsychiatr Dis Treat20139152124143101
   PubMed Web of Science ®Google Scholar
• GitlinMJSwendsenJHellerTLHammenCRelapse and impairment in bipolar disorderAm J Psychiatry199515211163516407485627
   PubMed Web of Science ®Google Scholar
• FountoulakisKNKasperSAndreassenOEfficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatryEur Arch Psychiatry Clin Neurosci2012262114822622948
   PubMed Web of Science ®Google Scholar
• BauerMRitterPGrunzeHPfennigATreatment options for acute depression in bipolar disorderBipolar Disord201214s2375022510035
   PubMed Web of Science ®Google Scholar
• SienaertPLambrichtsLDolsADe FruytJEvidence-based treatment strategies for treatment-resistant bipolar depression: a systematic reviewBipolar Disord2013151616923190379
   PubMed Web of Science ®Google Scholar
• FountoulakisKNGazouliMKelsoeJAkiskalHThe pharmaco-dynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorderEur Neuropsychopharmacol201425333534225596883
   PubMed Web of Science ®Google Scholar
• Lurasidone HCl | C28H37ClN4O2S – PubChem Available from: http://pubchem.ncbi.nlm.nih.gov/compound/11237860Accessed March 23, 2015
   Google Scholar
• CacciaSPasinaLNobiliACritical appraisal of lurasidone in the management of schizophreniaNeuropsychiatr Dis Treat2012815522570547
   PubMed Web of Science ®Google Scholar
• IshibashiTHorisawaTTokudaKPharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activityJ Pharmacol Exp Ther2010334117118120404009
   PubMed Web of Science ®Google Scholar
• IshiyamaTTokudaKIshibashiTItoATomaSOhnoYLurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801- induced impairment of learning and memory in the rat passive-avoidance testEur J Pharmacol2007572216017017662268
   PubMed Web of Science ®Google Scholar
• BjörklundMSirviöJRiekkinenMSallinenJScheininMRiekkinenPOverexpression of alpha2C-adrenoceptors impairs water maze navigationNeuroscience199995248148710658628
   PubMed Web of Science ®Google Scholar
• BanasrMHeryMPrintempsRDaszutaASerotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zoneNeuropsychopharmacology200429345046014872203
   PubMed Web of Science ®Google Scholar
• SchreiberRNewman-TancrediAImproving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT 1A receptor activationNeurobiol Learn Mem2014110728024423786
   PubMed Web of Science ®Google Scholar
• CitromeLLurasidone in schizophrenia: new information about dosage and place in therapyAdv Ther2012291081582523001538
   PubMed Web of Science ®Google Scholar
• WesolowskaANikiforukAStachowiczKTatarczyńskaEEffect of the selective 5-HT 7 receptor antagonist SB 269970 in animal models of anxiety and depressionNeuropharmacology200651357858616828124
   PubMed Web of Science ®Google Scholar
• GuscottMBristowLJHadinghamKGenetic knockout and pharmacological blockade studies of the 5-HT 7 receptor suggest therapeutic potential in depressionNeuropharmacology200548449250215755477
   PubMed Web of Science ®Google Scholar
• HuangMHoriguchiMFelixARMeltzerHY5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine effluxNeurore-port2012237436440
   Web of Science ®Google Scholar
• LuoniABerryACalabreseFDelayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescenceEur Neuropsychopharmacol201424698699524440552
   PubMed Web of Science ®Google Scholar
• CastrénERantamäkiTThe role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticityDev Neurobiol201070528929720186711
   PubMed Web of Science ®Google Scholar
• MeyerJMLoebelADSchweizerELurasidone: a new drug in development for schizophreniaExpert Opin Investig Drugs2009181117151726
   PubMed Web of Science ®Google Scholar
• KroezeWKHufeisenSJPopadakBAH1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugsNeuropsychopharmacology200328351952612629531
   PubMed Web of Science ®Google Scholar
• ReynoldsGPHillMJKirkSLThe 5-HT2C receptor and antipsychoticinduced weight gain–mechanisms and geneticsJ Psychopharmacol2006204 suppl151816785265
   PubMedGoogle Scholar
• TerryAVMahadikSPTime-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanismJ Pharmacol Exp Ther2007320396196816966470
   PubMed Web of Science ®Google Scholar
• UchidaHTakeuchiHGraff-GuerreroASuzukiTWatanabeKMamoDCDopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysisJ Clin Psychopharmacol201131449750221694629
   PubMed Web of Science ®Google Scholar
• Sunovion Pharmaceuticals IncLatuda® (lurasidone HCI tablets) [prescribing information]2013
   Google Scholar
• LoebelACucchiaroJSilvaRLurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled studyAm J Psychiatry2014171216016824170180
   PubMed Web of Science ®Google Scholar
• LoebelACucchiaroJSilvaRLurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled studyAm J Psychiatry2014171216917724170221
   PubMed Web of Science ®Google Scholar
• CitromeLKetterTACucchiaroJLoebelAClinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmedJ Affect Disord2014155202724246116
   PubMed Web of Science ®Google Scholar
• CitromeLCompelling or irrelevant? Using number needed to treat can help decideActa Psychiatr Scand2008117641241918479317
   PubMed Web of Science ®Google Scholar
• ThaseMEMacfaddenWWeislerRHBOLDER II Study GroupEfficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)J Clin Psychopharmacol200626660060917110817
   PubMed Web of Science ®Google Scholar
• CalabreseJRKeckPEJrMacfaddenWA randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depressionAm J Psychiatry200516271351136015994719
   PubMed Web of Science ®Google Scholar
• AstraZenecaSeroquel (quetiapine fumarate)2011 Available from: http://www1.astrazeneca-us.com/pi/Seroquel.pdfAccessed May 25, 2015
   Google Scholar
• TohenMVietaECalabreseJEfficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depressionArch Gen Psychiatry200360111079108814609883
   PubMed Web of Science ®Google Scholar
• EliLSymbyax (symbyax (olanzapine and fluoxetine hydrochloride)2013 Available from: http://pi.lilly.com/us/symbyax-pi.pdfAccessed May 25, 2015
   Google Scholar
• LeuchtSCiprianiASpineliLComparative efficacy and toler-ability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet2013382989695196223810019
   PubMed Web of Science ®Google Scholar
• Sunovion Pharmaceuticals IncThe US Food and Drug Administration approved Latuda^® (lurasidone HCl) for the treatment of adult patients with depressive episodes associated with bipolar I disorder (bipolar depression), both as monotherapy and as an adjunct to lithium or valproate2013 Available from: http://www.sunovion.com/news/latuda-press-room.htmlAccessed March 21, 2015
   Google Scholar
• CitromeLLurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychoticInt J Clin Pract201165218921021129135
   PubMed Web of Science ®Google Scholar
• De HertMYuWDetrauxJSweersKvan WinkelRCorrellCUBody weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorderCNS Drugs201226973375922900950
   PubMed Web of Science ®Google Scholar
• CitromeLIloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychoticsPostgrad Med2011123215316221474903
   PubMed Web of Science ®Google Scholar
• CitromeLWeidenPJMcEvoyJPEffectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension studyCNS Spectr2014190433033924330868
   PubMed Web of Science ®Google Scholar
• LoebelACucchiaroJXuJSarmaKPikalovAKaneJMEffectiveness of lurasidone vs quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority studySchizophr Res201314719510223583011
   PubMed Web of Science ®Google Scholar
• CitromeLCucchiaroJSarmaKLong-term safety and toler-ability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled studyInt Clin Psychopharmacol201227316517622395527
   PubMed Web of Science ®Google Scholar
• SamalinLGarnierMLlorcaP-MClinical potential of lurasidone in the management of schizophreniaTher Clin Risk Manag2011723921753886
   PubMed Web of Science ®Google Scholar
• McIntyreRSChaDSAlsuwaidanMMcIntoshDPowellAMJerrellJMA review of published evidence reporting on the efficacy and pharmacology of lurasidoneExpert Opin Pharmacother201213111653165922559286
   PubMed Web of Science ®Google Scholar
• KantrowitzJTCitromeLLurasidone for Schizophrenia: What’s different?Expert Review of Neurotherapeutics201212326527322364325
   PubMed Web of Science ®Google Scholar
• CucchiaroCJosephine PikalovAOgasaMSafety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophreniaInt J Neuropsychopharmacol201013suppl 121719691873
   PubMed Web of Science ®Google Scholar
• PotkinSGOgasaMCucchiaroJLoebelADouble-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorderSchizophr Res2011132210110721889878
   PubMed Web of Science ®Google Scholar
• FindlayLJEl-MallakhPEl-MallakhRSManagement of bipolar I depression: clinical utility of lurasidoneTher Clin Risk Manag2015117525609973
   PubMed Web of Science ®Google Scholar
• PreskornSEreshefskyLChiuY-YPoolaNLoebelAEffect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studiesHum Psychopharmacol201328549550524014143
   PubMed Web of Science ®Google Scholar
• EhretMJSopkoMAJrLemieuxTFocus on lurasidone: a new atypical antipsychotic for the treatment of schizophreniaFormulary201045313317
   Google Scholar
• RadoJJanicakPGPharmacological and clinical profile of recently approved second-generation antipsychoticsDrugs Aging2012291078379123018584
   PubMed Web of Science ®Google Scholar
• AddingtonDEPantelisCDineenMBenattiaIRomanoSJEfficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trialJ Clin Psychiatry200465121624163315641867
   PubMed Web of Science ®Google Scholar
• OhGHYuJ-CChoiK-SJooE-JJeongSHSimultaneous comparison of efficacy and tolerability of second-generation antipsychotics in schizophrenia: mixed-treatment comparison analysis based on head-to-head trial dataPsychiatry Investig20151214654
   Web of Science ®Google Scholar